Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

How I treat high-risk myeloma

Sagar Lonial, Lawrence H. Boise, Jonathan Kaufman

Blood (2015) 126 (13): 1536–1543.

https://doi.org/10.1182/blood-2015-06-653261

Published: 2015

Journal Articles

Platelet and Fibrin Alterations on Thromboelastography in Children Undergoing Congenital Cardiac Surgery with Cardiopulmonary Bypass

Kim S. John, MD, Elizabeth Villalobos-Menuey, MS, Matthew Hathaway, Abimbola Onasoga, PhD, Jonathan Kaufman, MD, Eduardo DaCruz, MD, Jorge DiPaola, MD, Marilyn J. Manco-Johnson, MD

Blood (2014) 124 (21): 4194.

https://doi.org/10.1182/blood.V124.21.4194.4194

Published: 2014

Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath

Blood (2009) 114 (22): 432.

https://doi.org/10.1182/blood.V114.22.432.432

Published: 2009

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Claire Torre, Amelia Langston, Mary J. Lechowicz, Christopher Flowers, Stephanie McMillan, Heather Renfroe, Leonard T Heffner, Edmund K Waller

Blood (2008) 112 (11): 3332.

https://doi.org/10.1182/blood.V112.11.3332.3332

Published: 2008

Journal Articles

A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Dixil Francis, Chatchada Karanes, Suzanne Trudel, Donna E. Reece, MD, Amrita Krishnan, Marc Buacharern, Renee Smith, Faraz Zaman, Engin Gul, Akari M. Dollard, Donald Harvey, Jonathan Kaufman

Blood (2008) 112 (11): 3706.

https://doi.org/10.1182/blood.V112.11.3706.3706

Published: 2008

Journal Articles

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD, Stephanie McMillan, RN, Leonard T. Heffner, MD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD, Morgan L. McLemore, MD, Rajni Sinha, MD, Mary J Lechowicz, MD, H. Jean Khoury, MD, Elliott F. Winton, MD

Blood (2008) 112 (11): 3644.

https://doi.org/10.1182/blood.V112.11.3644.3644

Published: 2008

Journal Articles

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Jonathan Kaufman, MD, Ruben Niesvizky, MD, Edward A. Stadtmauer, MD, Asher Chanan-Khan, MD, David Siegel, MD, PhD, Heather Horne, Nick Teoh, PhD, Matthew J. Leoni, MD, William A Wegener, MD, PhD, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 3697.

https://doi.org/10.1182/blood.V112.11.3697.3697

Published: 2008

Journal Articles

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

Amitabha Mazumder, MD, Jonathan Kaufman, MD, Sagar Lonial, MD, Sundar Jagannath, MD, David Vesole, MD, PhD

Blood (2007) 110 (11): 3612.

https://doi.org/10.1182/blood.V110.11.3612.3612

Published: 2007

Journal Articles

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

Andrzej Jakubowiak, Todd Zimmerman, Melissa Alsina, Paul Richardson, Jonathan Kaufman, T. Kendall, C. Brozo, A. McAllister, C. Leister, T. Hideshima, P. Sportelli, L. Gardner, R. Birch, I.C. Henderson, K. Giusti, Kenneth Anderson

Blood (2007) 110 (11): 1169.

https://doi.org/10.1182/blood.V110.11.1169.1169

Published: 2007

Journal Articles

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

Sagar Lonial, MD, Jonathan Kaufman, MD, Amelia A. Langston, MD, Leonard T. Heffner, MD, Claire Torre, Mary J. Lechowicz, MD, Christopher Flowers, MD, Stephanie McMillan, RN, Michael Arnold, Ned K. Waller, MD, PhD

Blood (2007) 110 (11): 949.

https://doi.org/10.1182/blood.V110.11.949.949

Published: 2007

Journal Articles

T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT).

Laura Vann, Milcah Larks, MD, Christopher Flowers, MD, Sagar Lonial, MD, Jonathan Kaufman, MD, Mary Jo Lechowicz, MD, Amelia A. Langston, MD, Jean Khoury, MD, Ned Waller, MD,PhD

Blood (2006) 108 (11): 3224.

https://doi.org/10.1182/blood.V108.11.3224.3224

Published: 2006

NARROW

How I treat high-risk myeloma

Platelet and Fibrin Alterations on Thromboelastography in Children Undergoing Congenital Cardiac Surgery with Cardiopulmonary Bypass

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma

Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients.

A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.

A Randomized Phase I Trial of Melphalan + Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration.

T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only